1. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Issue 10326 (19th February 2022) Authors: Wykoff, Charles C; Abreu, Francis; Adamis, Anthony P; Basu, Karen; Eichenbaum, David A; Haskova, Zdenka; Lin, Hugh; Loewenstein, Anat; Mohan, Shaun; Pearce, Ian A; Sakamoto, Taiji; Schlottmann, Patricio G; Silverman, David; Sun, Jennifer K; Wells, John A; Willis, Jeffrey R; Tadayoni, Ramin; Aaber... Journal: Lancet Issue: Volume 399:Issue 10326(2022) Page Start: 741 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗